スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - kapseln - olaparibum 50 mg, macrogolglyceridorum laurates, kapselhülle: hypromellosum, e 171, gellani gummi, kalii acetas, drucktinte: lacca, e 172 (nigrum), pro capsula. - onkologikum - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - filmtabletten - olaparibum 100 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.236 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - filmtabletten - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

欧州連合 - ドイツ語 - EMA (European Medicines Agency)

astrazeneca ab - olaparib - eierstock-neoplasmen - antineoplastische mittel - eierstock cancerlynparza ist angezeigt als monotherapie zur erhaltungstherapie von erwachsenen patienten mit fortgeschrittenem (figo-stadien iii und iv) brca1/2-mutierten (keimbahn und/oder somatisch) high-grade-epithelialen eierstockkrebs, eileiterkrebs oder primärem peritonealkarzinom, die in reaktion (vollständige oder teilweise) nach abschluss der first-line-chemotherapie auf platinbasis. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 und 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. sollten patienten, die zuvor behandelt wurden, mit einem anthrazyklin und einem taxan in der (neo)adjuvanten oder metastasierten setting, es sei denn, die patienten waren nicht geeignet für diese behandlung (siehe abschnitt 5. patienten mit hormon-rezeptor (hr)-positivem brustkrebs sollten auch fortgeschritten, die am oder nach vorheriger endokriner therapie, oder werden als ungeeignet für die endokrine therapie. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - rucaparibum - filmtabletten - rucaparibum 200 mg ut rucaparibi camsilas, cellulosum microcristallinum, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, poly(alcohol vinylicus), macrogolum 4000, talcum, e 171, e 132, e 133, pro compresso obducto corresp. natrium max. 1.2 mg. - ovarial-, eileiter- oder primäres peritonealkarzinom - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - rucaparibum - filmtabletten - rucaparibum 250 mg ut rucaparibi camsilas, cellulosum microcristallinum, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, poly(alcohol vinylicus), macrogolum 4000, talcum, e 171, pro compresso obducto corresp. natrium max. 1.5 mg. - ovarial-, eileiter- oder primäres peritonealkarzinom - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

mmpharm gmbh - rucaparibum - filmtabletten - rucaparibum 300 mg ut rucaparibi camsilas, cellulosum microcristallinum, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, poly(alcohol vinylicus), macrogolum 4000, talcum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium max. 1.8 mg. - ovarial-, eileiter- oder primäres peritonealkarzinom - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - niraparibum - filmtabletten - niraparibum 100 mg ut niraparibi tosilas monohydricus, cellulosum microcristallinum, lactosum monohydricum 34.66 mg, povidonum k 30, crospovidonum, silica colloidalis hydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - niraparibum, abirateroni acetas - filmtabletten - niraparibum 50 mg ut niraparibi tosilas monohydricus 79.7 mg, abirateroni acetas 500 mg corresp. abirateronum 446 mg, hypromellosum, natrii laurilsulfas, lactosum 240.54 mg ut lactosum monohydricum, crospovidonum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, glyceroli monocaprylocapras, talcum, natrii laurilsulfas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 5.05 mg. - prostatakarzinom - synthetika

スイス - ドイツ語 - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - niraparibum, abirateroni acetas - filmtabletten - niraparibum 100 mg ut niraparibi tosilas monohydricus 159.4 mg, abirateroni acetas 500 mg corresp. abirateronum 446 mg, hypromellosum, natrii laurilsulfas, lactosum 240.54 mg ut lactosum monohydricum 253.2 mg, crospovidonum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, glyceroli monocaprylocapras, talcum, natrii laurilsulfas, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 5.06 mg. - prostatakarzinom - synthetika